echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Invest: H3.3K27M specific vaccine response in diffuse midline glioma

    J Clin Invest: H3.3K27M specific vaccine response in diffuse midline glioma

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Diffuse midline gliomas (DMGs), including diffuse intrinsic gliomas (DIPG), have unsatisfactory results.


    The study included newly diagnosed patients, aged 3-21 years, with HLA-A*02.


    Diagnostic immunity

     

    As a result, a total of 19 patients joined the A layer (median age 11 years), and 10 patients joined the B layer (median age 13 years).


    In summary, the results of this study show that the H3.


     

    Original source:

     

    Sabine Mueller, et al.


    ncbi.
    nlm.
    nih.
    gov/32817593/" target="_blank" rel="noopener">Mass cytometry detects H3.
    3K27M-specific vaccine responses in diffuse midline gliom in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.